Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity.
Graves, J.D., Kordich, J.J., Huang, T.H., Piasecki, J., Bush, T.L., Sullivan, T., Foltz, I.N., Chang, W., Douangpanya, H., Dang, T., O'Neill, J.W., Mallari, R., Zhao, X., Branstetter, D.G., Rossi, J.M., Long, A.M., Huang, X., Holland, P.M.(2014) Cancer Cell 26: 177-189
- PubMed: 25043603 
- DOI: 10.1016/j.ccr.2014.04.028
- Primary Citation of Related Structures:  
4N90 - PubMed Abstract: 
Death receptor agonist therapies have exhibited limited clinical benefit to date. Investigations into why Apo2L/TRAIL and AMG 655 preclinical data were not predictive of clinical response revealed that coadministration of Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in vivo ...